Abbisko Cayman Limited (2256.HK) Financials
2256.HK Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2025 | 2.7 billion | 238.8 million |
| March 31, 2025 | 2.6 billion | 233.4 million |
| Dec. 31, 2024 | 2.2 billion | 158.2 million |
| Sept. 30, 2024 | 2.3 billion | 164.7 million |
2256.HK Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2025 | 165.0 million | 4.2 million |
| March 31, 2025 | 161.3 million | 4.1 million |
| Dec. 31, 2024 | -93.2 million | 6.4 million |
| Sept. 30, 2024 | -97.0 million | 6.7 million |
2256.HK Net Income
No data available :(
2256.HK Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2025 | 2.6 billion | 12.4 million | 19.5 million |
| March 31, 2025 | 2.6 billion | 12.1 million | 19.0 million |
| Dec. 31, 2024 | 2.1 billion | 14.1 million | 25.8 million |
| Sept. 30, 2024 | 2.2 billion | 14.7 million | 26.9 million |
2256.HK Shares Outstanding
2256.HK Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2025 | 1.2 million | 124.9 million | 19.4 million | - |
| March 31, 2025 | 1.2 million | 122.1 million | 19.0 million | - |
| Dec. 31, 2024 | 434111 | 125.7 million | 18.0 million | - |
| Sept. 30, 2024 | 451920 | 130.9 million | 18.8 million | - |
2256.HK Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2025 | 335.4 million | - |
| March 31, 2025 | 327.8 million | - |
| Dec. 31, 2024 | 3.6 million | - |
| Sept. 30, 2024 | 3.7 million | - |
2256.HK
Price: HK$9.03
52 week price:
Earnings Per Share: 0.26 HKD
P/E Ratio: 42.88
Exchange: HKG
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 7.4 billion